RxDoctor Payments Data

William Dabdoub, DPM

Foot & Ankle Surgery · Slidell, LANPI 1972558500

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,852 of the $2,542 with a category attached, or 72.8%. 8 manufacturers reported payments, led by Organogenesis Inc. at 30.8% of the total. Reporting peaked in 2019 at $787 and has fallen 52.2% since, to $376 in 2024. That places this record below the midpoint for foot & ankle surgery clinicians in LA, where the typical reported total is $2,260.

$2,542in general payments, 2019–2025

Across 54 payments — averaging $47.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$784
  • ALON Medical Technology$677
  • Stryker$596
  • Smith+Nephew$181
  • Johnson & Johnson$177
  • Hartmann USA, Inc.$100
  • plus $28 from 2 others

What the payments were for

  • Speaking & faculty fees$131%
  • Food & beverage$1,85273%
  • Education$67727%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,542 in reported general payments places this provider in the 50th percentile of 92 foot & ankle surgery providers in Louisiana.

See all foot & ankle surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$14,074
Medicare patients
117
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$603
Ammonium Lactate16$357
Fluconazole29$231
Meloxicam55$148
Allopurinol22$74
Clotrimazole13$57

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →